Glycoprotein-D-adjuvant vaccine to prevent genital herpes

New England Journal of Medicine

Volumn 347, Issue 21, 2002, Pages 1652-1661

  Stanberry, Lawrence R ^{a,b,c,d,e,f,g,h,i}   Spruance, Spotswood L ^{a,b,c,d,e,f,g,h,i}   Cunningham, Anthony L ^{a,b,c,d,e,f,g,h,i}   Bernstein, David I ^{a,b,c,d,e,f,g,h,i}   Mindel, Adrian ^{a,b,c,d,e,f,g,h,i}   Sacks, Stephen ^{a,b,c,d,e,f,g,h,i}   Tyring, Stephen ^{a,b,c,d,e,f,g,h,i}   Aoki, Fred Y ^{a,b,c,d,e,f,g,h,i}   Slaoui, Moncef ^{a,b,c,d,e,f,g,h,i}   Denis, Martine ^{a,b,c,d,e,f,g,h,i}   Vandepapeliere, Pierre ^{a,b,c,d,e,f,g,h,i}   Dubin, Gary ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c WESTMEAD HOSPITAL   (Australia)

^d WESTERN SYDNEY SEXUAL HEALTH CENTRE   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Cincinnati Children's Hospital   (United States)

^g Viridae Clinical Sciences   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN D; GLYCOPROTEIN D VACCINE; HERPES VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; SEXUAL BEHAVIOR; SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MIDDLE AGED; VIRAL ENVELOPE PROTEINS;

EID: 0037153024     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011915     Document Type: Article

References (34)

1. Reeves WC, Corey L, Adams HG, Vontver LA, Holmes KK. Risk of recurrence after first episodes of genital herpes: Relation to HSV type and antibody response. N Engl J Med 1981;305:315-9.
2. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med 1989;110:822-7.
3. Koutsky, LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992;326:1533-9.
4. Skoldenberg B, Jeansson S, Wolontis S. Herpes simplex virus type 2 and acute aseptic meningitis: Atypical features of cases with isolation of herpes simplex virus from cerebrospinal fluids. Scand J Infect Dis 1975;7:227-32.
5. Corey L, Spear PG. Infections with herpes simplex viruses. N Engl J Med 1986;314:749-57.
6. Carney O, Ross E, Bunker C, Ikkos G, Mindel A. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med 1994;70:40-5.
7. Mindel A. Psychological and psychosexual implications of herpes simplex virus infections. Scand J Infect Dis Suppl 1996;100:27-32.
8. Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999;75:398-402.
9. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
10. Cunningham AL, Mindel A, Dwyer DE. Epidemiology of sexually transmitted diseases. In: Stanberry LR, Bernstein DI, eds. Sexually Transmitted Diseases: Vaccines, Prevention and Control. San Diego, Calif.: Academic Press, 2000:3-42.
11. af Geijersstam V, Wang Z, Lewensohn-Fuchs I, et al. Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989. Int J Cancer 1998;76:341-4.
12. Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000;30:549-66.
13. Thoelen S, De Clercq N, Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 2001;19:2400-3.
14. Leroux-Roels G, Moreau E, Desombere I, et al. Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex (gD2t) candidate vaccine with MPL. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., October 4-7, 1994. Washington, D.C.: American Society for Microbiology, 1994:205. abstract.
15. Francotte M, Pala P, Van Opstal O, et al. Comparative safety and immunogenicity of two adjuvant formulations of an HSV-2 glycoprotein D based subunit vaccine in man. In: Abstracts of the 18th International Herpesvirus Workshop, Pittsburgh, July 25-30, 1993. Pittsburgh: University of Pittsburgh, 1993:C38. abstract.
16. Ashley RL, Wald A. Genital herpes: Review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999;12:1-8.
17. Kimura H, Shibata M, Kuzushima K, Nishikawa K, Nishiyama Y, Morishima T. Detection and direct typing of herpes simplex virus by polymerase chain reaction. Med Microbiol Immunol (Berl) 1990;179:177-84.
18. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science 1999;283:1277-8.
19. Su Z, Stevenson MM. Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection. Infect Immun 2000;68:4399-406.
20. Wilcoxen SC, Kirkman E, Dowdell KC, Stohlman SA. Gender-dependent IL-12 secretion by APC is regulated by IL-10. J Immunol 2000;164:6237-43.
21. Kim S, Voskuhl RR. Decreased IL-12 production underlies the decreased ability of male lymph node cells to induce experimental autoimmune encephalomyelitis, J Immunol 1999;162:5561-8.
22. Han X, Lundberg P, Tanamachi B, Openshaw H, Longmate J, Cantin E. Gender influences herpes simplex virus type I infection in normal and gamma interferon-mutant mice. J Virol 2001;75:3048-52. [Erratum, J Virol 2001;75:7789.]
23. Barna M, Komatsu T, Bi Z, Reiss CS. Sex differences in susceptibility to viral infection of the central nervous system. J Neuroimmunol 1996;67:31-9.
24. Wunderlich F, Maurin W, Benten WP, Schmitt-Wrede HP. Testosterone impairs efficacy of protective vaccination against P. chabaudi malaria. Vaccine 1993;11:1097-9.
25. Deshpande SP, Kumaraguru U, Rouse BT. Why do we lack an effective vaccine against herpes simplex virus infections? Microbes Infect 2000;2:973-8.
26. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. JAMA 1999;282:331-40.
27. Langenberg AGM, Corey L, Ashley R-L, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. N Engl J Med 1999;341:1432-8.
28. Singh M, Carlson JR, Briones M, et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 1998;16:1822-7.
29. Hermand P, Fabry L, Garcon N, et al. Effect of adjuvants on the immunogenicity of a recombinant herpes simplex virus glycoprotein D vaccine in the guinea pig model of HSV-2 infection. In: Abstracts of the 17th International Herpesvirus Workshop, Edinburgh, Scotland, August 1-7, 1992:376. abstract.
30. Hermand P, Fabry L, Garcon N, et al. Comparison of adjuvant efficacy of a recombinant herpes simplex virus glycoprotein D vaccine in primates. In: Abstracts of the 17th International Herpesvirus Workshop, Edinburgh, Scotland, August 1-7, 1992:388. abstract.
31. Bastin C, Hermand P, Francotte M, Garcon N, Slaoui M, Pala P. Synergistic association of adjuvants QS21 and MPL for induction of cytolytic T-lymphocytes and T-helper responses to recombinant protein antigens. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., October 4-7, 1994. Washington, D.C.: American Society for Microbiology, 1994:26. abstract.
32. Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T-cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 1999;17:2517-27.
33. Cunningham AL, Mikloska Z. The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes 2001;8:Suppl 1:6A-10A.
34. Simmons A, Nash AA. Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. J Virol 1984;52:816-21.